Nav: Home

Modern chemo better than second targeted hormone therapy against resistant prostate cancer

September 30, 2019

A modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows.

Men who had stopped responding to either abiraterone or enzalutamide lived longer before their disease came back when treated with the chemotherapy cabazitaxel than those offered the other targeted treatment.

The results suggest that cancer's lethal ability to develop drug resistance can affect the response not just to one treatment, but across precision medicines that work in a similar way.

Carefully considering the order in which treatments are offered to patients could help manage the impact of drug resistance and could extend the lives of men with advanced prostate cancer.

A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, led the UK arm of an international trial comparing the benefit of cabazitaxel chemotherapy and targeted hormone therapy in men with advanced prostate cancer.

The trial looked at 250 men who had previously been treated with another chemotherapy, docetaxel, and with one of the targeted therapies, abiraterone or enzalutamide - and whose disease progressed after less than a year on the targeted treatment.

The study, presented today (Monday) at the European Society of Medical Oncology conference in Barcelona and published simultaneously in the prestigious New England Journal of Medicine, was funded by Sanofi, the manufacturer of cabazitaxel.

The researchers found that on average, men treated with cabazitaxel lived twice as long before their cancer came back than those treated with abiraterone or enzalutamide - eight months compared with four months.

Overall, men treated with cabazitaxel lived for an average of 14 months compared with 11 months for men given abiraterone or enzalutamide.

The researchers believe that when one targeted drug stops working, a patient's cancer also develops resistance to other precision drugs that are aimed at similar weaknesses in the tumour.

Abiraterone - discovered at The Institute of Cancer Research (ICR), and developed with The Royal Marsden - and enzalutamide both exploit prostate cancers' dependence on androgen hormones to grow, by blocking the body's ability to produce or respond to them, respectively.

The study sheds further light on the importance of understanding the mechanisms by which cancers evolve to become resistant to targeted treatments.

Overcoming cancer's lethal ability to evolve in response to treatment will be the main focus of the ICR's new Centre for Cancer Drug Discovery.

The ICR needs to raise £14 million to complete the new Centre, which will bring together evolutionary scientists and drug discovery researchers to carry out a pioneering 'Darwinian' drug discovery programme.

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"Our new clinical trial has shown that a modern chemotherapy drug is more effective for men with advanced prostate cancer than giving them a targeted hormone treatment where they have already developed resistance to another.

"Our findings demonstrate the challenge we can face of cross-resistance between targeted therapies where they have similar mechanisms of action.

"We need to harness our knowledge of which drugs patients have received and of the biology of drug resistance, so we can offer men the sequence of treatments that is likely to benefit them most."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"Precision medicines such as abiraterone have been revolutionary for men with advanced prostate cancer - but while targeted treatments like this are often initially very effective, drug resistance is a major problem.

"In our new Centre for Cancer Drug Discovery, we aim to harness evolutionary science to create exciting new approaches to treatment that can anticipate and overcome drug resistance."
-end-
For more information please contact Sarah Wells in the ICR press office on 020 7153 5582 or sarah.wells@icr.ac.uk. For enquiries out of hours, please call 07595 963 613.

Notes to editors


The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations. Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top centres for cancer research and treatment globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

A college of the University of London, the ICR is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

Institute of Cancer Research

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
More Cancer News and Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.